ApoA1 infusions in acute MI did not significantly reduce the composite endpoint in the AEGIS-II trial. However, an exploratory analysis suggested benefit at higher LDL levels.
New analysis of the REDUCE-IT trial suggested benefit of icosapent ethyl doesn't vary by Lp(a) level and confirmed risk for Lp(a) with high triglycerides but not cholesterol.
A phase 1 gene editing trial in patients with heterozygous familial hypercholesterolemia and atherosclerotic CVD was paused after abnormal lab results were seen.
Physicians should pay attention to patients with higher risks for not receiving treatment, such as women and patients with normal BMI, said researchers.